Title

Targeting Zymogen Activation To Control the Matriptase-Prostasin Proteolytic Cascade

Authors

Authors

Z. H. Xu; Y. W. Chen; A. Battu; P. Wilder; D. Weber; W. B. Yu; A. D. MacKerell; L. M. Chen; K. X. Chai; M. D. Johnson;C. Y. Lin

Comments

Authors: contact us about adding a copy of your work at STARS@ucf.edu

Abbreviated Journal Title

J. Med. Chem.

Keywords

HEPATOCYTE GROWTH-FACTOR; MEMBRANE SERINE-PROTEASE; PLASMINOGEN-ACTIVATOR; STROMAL CELLS; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; BREAST-CANCER; IN-VITRO; INHIBITOR; EXPRESSION; Chemistry, Medicinal

Abstract

Membrane-associated serine protease matriptase has been implicated in human diseases and might be a drug target. In the present study, a novel class of matriptase inhibitors targeting zymogen activation is developed by a combination of the screening of compound library using a cell-based matriptase activation assay and a computer-aided search of commercially available analogues of a selected compound. Four structurally related compounds are identified that can inhibit matriptase activation with IC(50) at low rnicromolar concentration in both intact-cell and cell-free systems, suggesting that these inhibitors target the matriptase autoactivation machinery rather than the intracellular signaling pathways. These activation inhibitors can also inhibit prostasin activation, a downstream event that occurs in lockstep with matriptase activation. In contrast, the matriptase catalytic inhibitor CVS-3983 at a concentration 300-fold higher than its K(i) fails to inhibit activation of either protease. Our results suggest that inhibiting matriptase activation is an efficient way to control matriptase function.

Journal Title

Journal of Medicinal Chemistry

Volume

54

Issue/Number

21

Publication Date

1-1-2011

Document Type

Article

Language

English

First Page

7567

Last Page

7578

WOS Identifier

WOS:000296408100013

ISSN

0022-2623

Share

COinS